Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial

特奈特普酶 溶栓 医学 冲程(发动机) 组织纤溶酶原激活剂 灌注扫描 纤溶剂 临床试验 灌注 内科学 外科 麻醉 心肌梗塞 机械工程 工程类
作者
Xin Cheng,Lan Hong,Leonid P. Churilov,Longting Lin,Yifeng Ling,Jin Zhang,Jianhong Yang,Yu Geng,Danhong Wu,Xueyuan Liu,Xiaoyu Zhou,Yuwu Zhao,Qijin Zhai,Liandong Zhao,Yangmei Chen,Ying Chen Guo,Xiaofei Yu,Fan Gong,Yi Sui,Gang Li
出处
期刊:Stroke and vascular neurology [BMJ]
卷期号:9 (5): 551-559 被引量:21
标识
DOI:10.1136/svn-2023-002820
摘要

BACKGROUND: The performance of intravenous tenecteplase in patients who had an acute ischaemic stroke with large/medium vessel occlusion or severe stenosis in an extended time window remains unknown. We investigated the promise of efficacy and safety of different doses of tenecteplase manufactured in China, in patients who had an acute ischaemic stroke with large/medium vessel occlusion beyond 4.5-hour time window. METHODS: The CHinese Acute tissue-Based imaging selection for Lysis In Stroke-Tenecteplase was an investigator-initiated, umbrella phase IIa, open-label, blinded-endpoint, Simon's two-stage randomised clinical trial in 13 centres across mainland China. Participants who had salvageable brain tissue on automated perfusion imaging and presented within 4.5-24 hours from time of last seen well were randomised to receive 0.25 mg/kg tenecteplase or 0.32 mg/kg tenecteplase, both with a bolus infusion over 5-10 s. The primary outcome was proportion of patients with promise of efficacy and safety defined as reaching major reperfusion without symptomatic intracranial haemorrhage at 24-48 hours after thrombolysis. Assessors were blinded to treatment allocation. All participants who received tenecteplase were included in the analysis. RESULTS: A total of 86 patients who had an acute ischaemic stroke identified with anterior large/medium vessel occlusion or severe stenosis were included in this study from November 2019 to December 2021. All of the 86 patients enrolled either received 0.25 mg/kg (n=43) or 0.32 mg/kg (n=43) tenecteplase, and were available for primary outcome analysis. Fourteen out of 43 patients in the 0.25 mg/kg tenecteplase group and 10 out of 43 patients in the 0.32 mg/kg tenecteplase group reached the primary outcome, providing promise of efficacy and safety for both doses based on Simon's two-stage design. DISCUSSION: Among patients with anterior large/medium vessel occlusion and significant penumbral mismatch presented within 4.5-24 hours from time of last seen well, tenecteplase 0.25 mg/kg and 0.32 mg/kg both provided sufficient promise of efficacy and safety. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT04086147, https://clinicaltrials.gov/ct2/show/NCT04086147).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
爆米花的应助被林泽伟采纳,获得10
刚刚
111发布了新的文献求助10
1秒前
2秒前
pluto的应助被科研通管家采纳,获得10
2秒前
赘婿的应助被科研通管家采纳,获得10
2秒前
DW的应助被科研通管家采纳,获得10
2秒前
科研路顺遂完成签到,获得积分10
2秒前
Hello的应助被科研通管家采纳,获得10
2秒前
wanci的应助被科研通管家采纳,获得10
2秒前
爆米花的应助被科研通管家采纳,获得10
2秒前
秋风的应助被科研通管家采纳,获得10
3秒前
完美世界的应助被科研通管家采纳,获得10
3秒前
所所的应助被科研通管家采纳,获得10
3秒前
小蘑菇的应助被科研通管家采纳,获得10
3秒前
没可就和的应助被科研通管家采纳,获得10
3秒前
爆米花的应助被科研通管家采纳,获得10
3秒前
香蕉觅云的应助被科研通管家采纳,获得30
3秒前
3秒前
pluto的应助被科研通管家采纳,获得10
4秒前
6666的应助被科研通管家采纳,获得10
4秒前
4秒前
JamesPei的应助被归璨采纳,获得10
4秒前
852的应助被科研通管家采纳,获得10
4秒前
wanci的应助被科研通管家采纳,获得10
4秒前
4秒前
4秒前
科目三的应助被七七采纳,获得10
6秒前
我是666完成签到,获得积分10
6秒前
6秒前
8秒前
8秒前
tt发布了新的文献求助10
9秒前
七月十八完成签到,获得积分10
9秒前
神勇的筝发布了新的文献求助10
10秒前
ldj完成签到 ,获得积分10
10秒前
Wlin发布了新的文献求助10
10秒前
何皮皮完成签到,获得积分10
10秒前
YeSun完成签到,获得积分10
11秒前
万能图书馆的应助被马小采纳,获得10
12秒前
李卓完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178960
求助须知:如何正确求助?哪些是违规求助? 9569638
关于积分的说明 21805682
捐赠科研通 7774071
什么是DOI,文献DOI怎么找? 3432955
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478640